Intestinal-Targeted FXR Agonists for Metabolic Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic and liver conditions associated with farnesoid X receptor (FXR) activity lack effective compounds that can specifically target FXR agonism for therapeutic benefits without systemic side effects.
Innovation Solution
Development of novel compounds, such as those represented by Formula (I) and their pharmaceutically acceptable salts or solvates, which act as farnesoid X receptor agonists, specifically designed for administration to enhance FXR target gene expression in the intestines while minimizing systemic plasma levels, thereby treating metabolic disorders and liver conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FXR agonist compounds are administered to treat metabolic and liver conditions, then therapeutic benefits are achieved through enhanced FXR target gene expression, but systemic side effects occur due to systemic plasma exposure
Solution Approach 1:
The patent applies local quality by designing compounds that achieve high concentrations specifically in the intestinal lumen while maintaining minimal systemic plasma levels. This is accomplished through molecular structures that facilitate intestinal targeting and limited absorption into systemic circulation, thereby providing therapeutic benefits at the intestinal site while avoiding systemic side effects.
Solution Approach 2:
The patent uses intestinal lumen as an intermediary compartment to deliver FXR agonist activity locally. The compounds act as intermediaries that bridge the need for systemic therapeutic effects with the desire to avoid systemic exposure, by concentrating their action in the intestinal lumen where they can exert therapeutic effects on metabolic conditions without entering systemic circulation in significant amounts.
2Quantity of substance
If compounds are designed to achieve high intestinal concentration, then FXR activation in intestines is enhanced, but achieving selective intestinal targeting without systemic distribution becomes difficult
Solution Approach 1:
The patent applies parameter changes by modifying molecular parameters of the FXR agonist compounds to optimize their physicochemical properties for intestinal targeting. This includes adjusting lipophilicity, molecular weight, and functional group composition to achieve optimal balance between intestinal permeability and systemic absorption, thereby enhancing intestinal concentration while maintaining selective targeting without excessive complexity.
Data Source
AI summary
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.